Resources
31 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 3/10/2024 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration's (SAMHSA) updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. It emphasizes harm reduction and access to treatment as essential aspects of overdose prevention.
Posted 9/8/2023 (updated 3/26/2024)
September 2023 is National Recovery Month and HRSA’s Office of Women’s Health has a toolkit to support organizations and health care providers that care for women living with opioid use disorder (OUD). The toolkit provides strategies to engage women with OUD, care coordination for support, and other resources.
Posted 8/15/2023 (updated 3/26/2024)
During this webinar, Aaron Ferguson and Dr. Janan Wyatt reviewed the evidence, including the cost benefit, of MOUD, and recent research findings on how regulatory changes affect patient experience.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.
Posted 2/28/2023 (updated 3/27/2024)
This study's objective was to develop and validate a survey tool to assess emergency department physician attitudes, clinical practice, and willingness to perform opiate harm reduction interventions. After surveying physicians, most showed they were willing to provide necessary interventions, while few do perform them. Although there was an increased willingness to perform the interventions, a disparity remains.
Posted 11/16/2022 (updated 3/27/2024)
In this cross-sectional study of 266 Medicaid MCO plans and 39 FFS programs, FFS programs offered more generous MOUD coverage, but a higher percentage of FFS programs imposed PA than MCO plans.
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).
Posted 3/15/2022 (updated 3/27/2024)
Pre- Pregnancy fact sheet. Information for Providers
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.